September 11, 2017 10:17 AM EDT
R&D

Ab­b­Vie stirs safe­ty jit­ters af­ter two pa­tients die in ABT-494 study

Arsalan Arif

Founder

Ab­b­Vie $AB­BV re­vealed that two rheuma­toid arthri­tis pa­tients died in its late-stage work on ABT-494, which quick­ly trig­gered a case of the jit­ters for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: CEO of Unit­ed­Health in­sur­ance unit shot and killed in New York in what po­lice call ‘a brazen, tar­get­ed ...

Lil­ly beats No­vo in bell­wether head-to-head weight loss study

As 23andMe strug­gles, an­oth­er ge­net­ic test­ing com­pa­ny bets on drug dis­cov­ery

GSK makes an­oth­er ADC deal, this time with BioN­Tech's part­ner Du­al­i­ty­Bio

Lil­ly drops body mass ranges from FDA la­bel for weight loss drug

Blue­bird and Ver­tex's sick­le cell gene ther­a­pies to kick off new Med­ic­aid ac­cess mod­el

A service from the Financial Times